Skip to main content

Articles

Page 1 of 6

  1. Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1. Although the introduction of tyrosine kinase inhibitors (TKIs) has substa...

    Authors: Theresa Klümper, Henrike Bruckmueller, Tobias Diewock, Meike Kaehler, Sierk Haenisch, Christiane Pott, Oliver Bruhn and Ingolf Cascorbi

    Citation: Experimental Hematology & Oncology 2020 9:26

    Content type: Research

    Published on:

  3. Novel corona virus caused pneumonia first reported in December, 2019 in Wuhan, China was later named COVID-19. Due to its special pathogenicity, COVID-19 transmitted with high speed beyond borders and has sign...

    Authors: Ehtisham Ul Haq, Jifeng Yu and Jiancheng Guo

    Citation: Experimental Hematology & Oncology 2020 9:24

    Content type: Letter to the Editor

    Published on:

  4. Pancreatic cancer continues to be one of the most aggressive malignant tumors. Work in recent years in cancer molecular biology has revealed that metabolic reprogramming is an additional hallmark of cancer tha...

    Authors: Mengqi Liu, Wensheng Liu, Yi Qin, Xiaowu Xu, Xianjun Yu, Qifeng Zhuo and Shunrong Ji

    Citation: Experimental Hematology & Oncology 2020 9:23

    Content type: Review

    Published on:

  5. Successful prevention of post-transplantation relapse after donor lymphocyte infusion (DLI) depends on its capability to mediate an effective graft-versus-leukemia (GVL) response while minimizing DLI-related t...

    Authors: Yong-Rim Kwon, Hye Joung Kim, Min-Jung Sohn, Ji-Young Lim, Kyung-Shin Park, Seok Lee, Nack-Gyun Chung, Dae-Chul Jeong, Chang-Ki Min and Yoo-Jin Kim

    Citation: Experimental Hematology & Oncology 2020 9:22

    Content type: Research

    Published on:

  6. Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined.

    Authors: José Luis Piñana, Rodrigo Martino, Irene García-García, Rocío Parody, María Dolores Morales, Gonzalo Benzo, Irene Gómez-Catalan, Rosa Coll, Ignacio De La Fuente, Alejandro Luna, Beatriz Merchán, Anabelle Chinea, Dunia de Miguel, Ana Serrano, Carmen Pérez, Carola Diaz…

    Citation: Experimental Hematology & Oncology 2020 9:21

    Content type: Research

    Published on:

  7. Despite the proven benefits of iron chelation therapy (ICT) in the management of chronic iron overload and related complications, compliance to long-term ICT is challenging. Results from the ECLIPSE study, an ...

    Authors: Immacolata Tartaglione, Raffaella Origa, Antonis Kattamis, Michael Pfeilstöcker, Sibel Gunes, Susanne Crowe, Niamh Fagan, Beatrice Vincenzi and Giovan Battista Ruffo

    Citation: Experimental Hematology & Oncology 2020 9:20

    Content type: Research

    Published on:

  8. To explore the efficacy of primary chemoradiation with cisplatin versus cetuximab with respect to HPV/p16 and smoking statuses.

    Authors: Il Seok Daniel Jeong, Huan Mo, Anthony Nguyen, Esther G. Chong, Hsin Hsiang Clarence Tsai, Justin Moyers, Matthew Kim, Curtis Lacy, Vivek Shah, Eric Lau, Yi Xu and Huynh Cao

    Citation: Experimental Hematology & Oncology 2020 9:19

    Content type: Letter to the Editor

    Published on:

  9. Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor response to chemo- and (modest-dose conventionally fractionated) radio-therapy. Emerging evidence suggests that pancreatic stellate cells (PSCs) se...

    Authors: Pei Pei Che, Alessandro Gregori, Omidreza Firuzi, Max Dahele, Peter Sminia, Godefridus J. Peters and Elisa Giovannetti

    Citation: Experimental Hematology & Oncology 2020 9:18

    Content type: Letter to the Editor

    Published on:

  10. PD-L1 expression and tumour mutational burden (TMB) are both associated with the responses of multiple tumours to immune checkpoint inhibitor (ICI) therapy. However, their prevalence and correlations may diffe...

    Authors: Yanhui Chen, Yating Wang, Hongli Luo, Xue Meng, Wei Zhu, Di Wang, Hui Zeng and Henghui Zhang

    Citation: Experimental Hematology & Oncology 2020 9:17

    Content type: Research

    Published on:

  11. Coronavirus disease 2019 (COVID-19) is a novel infectious viral disease, which lacks well-established diagnostic laboratory parameters that could be used to evaluate disease severity, thromboembolism or cardio...

    Authors: Changqian Bao, Xiandong Tao, Wei Cui, Bin Yi, Tiewen Pan, Ken H. Young and Wenbin Qian

    Citation: Experimental Hematology & Oncology 2020 9:16

    Content type: Research

    Published on:

  12. Chimeric antigen receptor (CAR) T cell therapy is a new frontier in cancer therapy. The toxicity of cytokine release syndrome (CRS) has become one of the major challenges that limits the wider use of CAR T cel...

    Authors: Zhaonian Hao, Ruyuan Li, Li Meng, Zhiqiang Han and Zhenya Hong

    Citation: Experimental Hematology & Oncology 2020 9:15

    Content type: Review

    Published on:

  14. Breast cancer is the most diagnosed malignancy in females in the United States. The members of retinal determination gene network (RDGN) including DACH, EYA, as well as SIX families participate in the prolifer...

    Authors: Bing Dong, Ming Yi, Suxia Luo, Anping Li and Kongming Wu

    Citation: Experimental Hematology & Oncology 2020 9:13

    Content type: Research

    Published on:

  15. Human prostate cancer spheres endowed with stem cell properties have been obtained from androgen-dependent cell line LNCaP after exposure to an epigenomic modulator phenethyl isothiocynate (PEITC). Sphere cell...

    Authors: Jingjing Wu, Shundong Cang, Christina Liu, Whitman Ochiai and Jen Wei Chiao

    Citation: Experimental Hematology & Oncology 2020 9:12

    Content type: Short report

    Published on:

  16. T cells expressing a chimeric antigen receptor (CAR) engineered to target CD19 can treat leukemia effectively but also increase the risk of complications such as cytokine release syndrome (CRS) and CAR T cell ...

    Authors: Liqing Kang, Xiaowen Tang, Jian Zhang, Minghao Li, Nan Xu, Wei Qi, Jingwen Tan, Xiaoyan Lou, Zhou Yu, Juanjuan Sun, Zhenkun Wang, Haiping Dai, Jia Chen, Guoqing Lin, Depei Wu and Lei Yu

    Citation: Experimental Hematology & Oncology 2020 9:11

    Content type: Research

    Published on:

  17. Immune cell infiltration in the tumor microenvironment (TME) affects tumor initiation, patients’ prognosis and immunotherapy strategies. However, their roles and interactions with genomics and molecular proces...

    Authors: Furong Liu, Lu Qin, Zhibin Liao, Jia Song, Chaoyi Yuan, Yachong Liu, Yu Wang, Heze Xu, Qiaofeng Zhang, Youliang Pei, Hongwei Zhang, Yonglong Pan, Xiaoping Chen, Zhanguo Zhang, Wanguang Zhang and Bixiang Zhang

    Citation: Experimental Hematology & Oncology 2020 9:10

    Content type: Research

    Published on:

  18. This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma c...

    Authors: Rasmus Strøm Risbjerg, Mie Vennize Hansen, Anne Sofie Sørensen and Tue Wenzel Kragstrup

    Citation: Experimental Hematology & Oncology 2020 9:9

    Content type: Letter to the Editor

    Published on:

  19. Multiple myeloma is an incurable hematological malignancy characterized by a heterogeneous genetic and epigenetic landscape. Although a number of genetic aberrations associated with myeloma pathogenesis, progr...

    Authors: Xi Yun Zhang, Deepa Rajagopalan, Tae-Hoon Chung, Lissa Hooi, Tan Boon Toh, Johann Shane Tian, Masturah Bte Mohd Abdul Rashid, Noor Rashidha Bte Meera Sahib, Mengjie Gu, Jhin Jieh Lim, Wilson Wang, Wee Joo Chng, Sudhakar Jha and Edward Kai-Hua Chow

    Citation: Experimental Hematology & Oncology 2020 9:8

    Content type: Research

    Published on:

  20. Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor contro...

    Authors: Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, Kyaw Z. Thein, Aung Naing, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Filip Janku, Funda Meric-Bernstam, Razelle Kurzrock and Gerald Falchook

    Citation: Experimental Hematology & Oncology 2020 9:7

    Content type: Research

    Published on:

  21. The efficacy and safety of rituximab (RTX) on hemolytic anemia (HA) is unknown. Therefore we retrospectively analyze the efficacy and safety of RTX in autoimmune hemolytic anemia (AIHA) and microangiopathic he...

    Authors: Shih-Hsuan Chao, Yuh-Lih Chang, Jiin-Cherng Yen, Hsien-Tzung Liao, Tsai-Hung Wu, Chia-Li Yu, Chang-Youh Tsai and Yueh-Ching Chou

    Citation: Experimental Hematology & Oncology 2020 9:6

    Content type: Research

    Published on:

  22. The high-risk refractory and/or relapsed (R/R) childhood acute leukemia prognosis is poor, and allogeneic stem cell transplantation (allo-HSCT) is the most prudent treatment modality. However, there are limite...

    Authors: Binglei Zhang, Jian Zhou, Fengkuan Yu, Tianxin Lv, Baijun Fang, Dandan Fan, Zhenyu Ji and Yongping Song

    Citation: Experimental Hematology & Oncology 2020 9:5

    Content type: Research

    Published on:

  24. The DNA hypomethylating agents (HMAs) decitabine and azacitidine have been widely used in the management of elderly patients with acute myeloid leukemia (AML). However, no direct clinical trials have been carr...

    Authors: Bingbing Wen, Weiwen You, Sitian Yang and Xin Du

    Citation: Experimental Hematology & Oncology 2020 9:3

    Content type: Review

    Published on:

  25. In this study, we retrospectively summarized the differences of molecular gene mutations between MDS and AML patients, as well as the young and older age groups of MDS and AML patients. We also analyzed the re...

    Authors: Jifeng Yu, Yingmei Li, Tao Li, Yafei Li, Haizhou Xing, Hui Sun, Ling Sun, Dingming Wan, Yanfang Liu, Xinsheng Xie and Zhongxing Jiang

    Citation: Experimental Hematology & Oncology 2020 9:2

    Content type: Research

    Published on:

  26. Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs). Second mitochondria-derived activator of caspases (SM...

    Authors: Brianna M. Craver, Thanh Kim Nguyen, Jenny Nguyen, Hellen Nguyen, Christy Huynh, Sarah J. Morse and Angela G. Fleischman

    Citation: Experimental Hematology & Oncology 2020 9:1

    Content type: Research

    Published on:

  27. Cancer cells with strong immunogenicity are susceptible for elimination by cancer immunoediting, while the subpopulations with weak immunogenicity survive. As a result, a subset of cancer cells evade the immun...

    Authors: Ming Yi, Bing Dong, Qian Chu and Kongming Wu

    Citation: Experimental Hematology & Oncology 2019 8:32

    Content type: Editorial

    Published on:

    The Article to this article has been published in Nature 2019 567:1032

  28. Considerable progress has been made in cancer therapeutics recently with targeted strategies that are efficacious and less toxic. Immunotherapy and chimeric antigen receptor (CAR) T-cells are increasingly bein...

    Authors: Muhammad Bilal Abid, Nirav N. Shah, Theresa C. Maatman and Parameswaran N. Hari

    Citation: Experimental Hematology & Oncology 2019 8:31

    Content type: Review

    Published on:

  29. Medulloblastoma is the most frequently occurring malignant brain tumor in children. Current treatment strategies for medulloblastoma include aggressive surgery, cranio-spinal irradiation and adjuvant chemother...

    Authors: Shanshan Zhang, Zhaojian Gong, Peter O. Oladimeji, Duane G. Currier, Qipan Deng, Ming Liu, Taosheng Chen and Yong Li

    Citation: Experimental Hematology & Oncology 2019 8:30

    Content type: Research

    Published on:

  30. DNA damage repair deficiency leads to the increased risk of genome instability and oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer treatment by inducing excessive geno...

    Authors: Ming Yi, Bing Dong, Shuang Qin, Qian Chu, Kongming Wu and Suxia Luo

    Citation: Experimental Hematology & Oncology 2019 8:29

    Content type: Review

    Published on:

  31. Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine k...

    Authors: Juanjuan Zhao, Yongping Song and Delong Liu

    Citation: Experimental Hematology & Oncology 2019 8:28

    Content type: Review

    Published on:

  32. The use of chimeric antigen receptor (CAR) T cell technology as a therapeutic strategy for the treatment blood-born human cancers has delivered outstanding clinical efficacy. However, this treatment modality c...

    Authors: Bill X. Wu, No-Joon Song, Brian P. Riesenberg and Zihai Li

    Citation: Experimental Hematology & Oncology 2019 8:27

    Content type: Editorial

    Published on:

  33. Recently, a series of clinical trials showed that combination of anti-programmed cell death-1 (α-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (α-CTLA-4) could effectively eliminate tumor. However...

    Authors: Kongju Wu, Ming Yi, Shuang Qin, Qian Chu, Xinhua Zheng and Kongming Wu

    Citation: Experimental Hematology & Oncology 2019 8:26

    Content type: Review

    Published on:

  34. The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of a...

    Authors: Julie H. Selim, Shagufta Shaheen, Wei-Chun Sheu and Chung-Tsen Hsueh

    Citation: Experimental Hematology & Oncology 2019 8:25

    Content type: Review

    Published on:

  35. Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L79...

    Authors: Stephen R. Fairclough, Lesli A. Kiedrowski, Jessica J. Lin, Ori Zelichov, Gabi Tarcic, Thomas E. Stinchcombe, Justin I. Odegaard, Richard B. Lanman, Alice T. Shaw and Rebecca J. Nagy

    Citation: Experimental Hematology & Oncology 2019 8:24

    Content type: Rapid communication

    Published on:

  36. Microvesicles as a new device of cell–cell communication are potentially able to induce some phenotypes and genotypes of an origin cell in a target cell. We evaluate the role of leukemia microvesicles on the l...

    Authors: Farnaz Razmkhah, Sorayya Ghasemi, Masoud Soleimani and Sedigheh Amini Kafi-abad

    Citation: Experimental Hematology & Oncology 2019 8:23

    Content type: Letter to the Editor

    Published on:

  37. The use of direct oral anticoagulant in cancer patients is an emerging issue, which seems to be an alternative to low molecular weight heparin. Every year several new drugs are approved as anticancer treatment...

    Authors: Daniele Santini, Fabrizio Citarella, Bruno Vincenzi, Marco Russano, Giuseppe Tonini and Marco Stellato

    Citation: Experimental Hematology & Oncology 2019 8:22

    Content type: Letter to the Editor

    Published on:

  38. The word of hemoglobinopathy is described for an array of disorders that affecting hemoglobin (Hb) functions. Hb is a molecule with 68 kDa molecular weight, serving as oxygen carrying metalloprotein. Hemoglobi...

    Authors: Zahra Mousavi, Zinat Yazdani, Alireza Moradabadi, Fatemeh Hoseinpourkasgari and Gholamhossein Hassanshahi

    Citation: Experimental Hematology & Oncology 2019 8:21

    Content type: Review

    Published on:

  39. Programmed death-1 (PD-1) inhibitors are among the immunotherapies that have revolutionized our approach to treating several cancers. These novel agents act by blocking PD-1 receptor/PD-1 ligand interactions t...

    Authors: Hoda Z. Pourhassan, David Tryon, Brett Schaeffer, Hamid Mirshahidi and John Wong

    Citation: Experimental Hematology & Oncology 2019 8:20

    Content type: Case report

    Published on:

  41. The human concentrative nucleoside transporter 1 (hCNT1) a product of the SLC28A1 gene is one of the three concentrative nucleoside transporters, with a substrate specificity for physiological pyrimidine nucleosi...

    Authors: Chunmei Wang and John K. Buolamwini

    Citation: Experimental Hematology & Oncology 2019 8:18

    Content type: Short report

    Published on:

  42. Large clonal populations of cells bearing PIG-A mutations are the sine qua non of PNH, but the PIG-A mutation itself is insufficient for clonal expansion. The association between PNH and aplastic anemia supports ...

    Authors: Camille Lobry, Ashish Bains, Leah B. Zamechek, Sherif Ibrahim, Iannis Aifantis and David J. Araten

    Citation: Experimental Hematology & Oncology 2019 8:17

    Content type: Research

    Published on:

  43. Therapy for chronic myeloid leukemia (CLL) is going through a major paradigm shift. Combination chemoimmunotherapy regimens have been the frontline therapies for CLL, whereas chlorambucil remained the standard...

    Authors: Delong Liu and Juanjuan Zhao

    Citation: Experimental Hematology & Oncology 2019 8:15

    Content type: Review

    Published on:

  44. The Bruton’s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models. We investigated how antib...

    Authors: Alexandra Albertsson-Lindblad, Catja Freiburghaus, Mats Jerkeman and Sara Ek

    Citation: Experimental Hematology & Oncology 2019 8:16

    Content type: Short report

    Published on:

  45. Monoclonal antibodies targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) (e.g., ipilimumab [IPI]) and the programmed cell death-1 (PD1) receptor (e.g., nivolumab [NIVO]) represent significant br...

    Authors: Ravi Potluri, Sandip Ranjan, Hitesh Bhandari, Helen Johnson, Andriy Moshyk and Srividya Kotapati

    Citation: Experimental Hematology & Oncology 2019 8:14

    Content type: Research

    Published on:

  47. Many cases of acute lymphoblastic leukemia (ALL) carry visible acquired chromosomal changes of pathogenetic, diagnostic, and prognostic importance. Nevertheless, from one-fourth to half of newly diagnosed ALL ...

    Authors: Ioannis Panagopoulos, Marta Brunetti, Margrethe Stoltenberg, Rønnaug A. U. Strandabø, Julie Staurseth, Kristin Andersen, Ilyá Kostolomov, Tarjei S. Hveem, Susanne Lorenz, Tove Anita Nystad, Trond Flægstad, Francesca Micci and Sverre Heim

    Citation: Experimental Hematology & Oncology 2019 8:12

    Content type: Case report

    Published on:

  48. Hepatoblastoma is the most common hepatic malignancy in children, accounting for approximately 80% of all childhood liver tumors. KRAS and NRAS, members of the RAS gene family, are closely linked to tumorigenesis...

    Authors: Tianyou Yang, Yang Wen, Jiahao Li, Tianbao Tan, Jiliang Yang, Jing Pan, Chao Hu, Yuxiao Yao, Jiao Zhang, Yijuan Xin, Suhong Li, Huimin Xia, Jing He and Yan Zou

    Citation: Experimental Hematology & Oncology 2019 8:11

    Content type: Research

    Published on:

  49. Myeloproliferative neoplasms (MPN) are heterogeneous diseases that classified by the presence of Philadelphia chromosome into Philadelphia chromosome negative (Ph-neg) and positive (Ph-pos) myeloproliferative ...

    Authors: Alireza Moradabadi, Alireza Farsinejad, Behzad Khansarinejad and Ahamd Fatemi

    Citation: Experimental Hematology & Oncology 2019 8:10

    Content type: Research

    Published on:

  50. Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effecti...

    Authors: Stefanie Jilg, Richard T. Hauch, Johanna Kauschinger, Lars Buschhorn, Timo O. Odinius, Veronika Dill, Catharina Müller-Thomas, Tobias Herold, Peter M. Prodinger, Burkhard Schmidt, Dirk Hempel, Florian Bassermann, Christian Peschel, Katharina S. Götze, Ulrike Höckendorf, Torsten Haferlach…

    Citation: Experimental Hematology & Oncology 2019 8:9

    Content type: Rapid communication

    Published on:

Submit manuscript

Follow

Annual Journal Metrics

On the blog

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us